Sarclisa (isatuximab-irfc)

Treatment regimens comprised lenalidomide (n = 36) or thalidomide (n = 15) with daratumumab, and pomalidomide (n = 2) with isatuximab. Most patients (n = 38) received frontline therapy, and all were given thromboprophylaxis according to guidelines, mainly aspirin (73%)...Given the limited number of patients and thrombotic events, and the cytokine data available for only two VTE cases, these associations should be regarded as exploratory and interpreted with caution. Overall, these exploratory findings warrant validation in larger, independent cohorts and may help generate hypotheses on how inflammatory signatures influence thrombotic risk and prophylaxis efficacy in MM patients receiving IMiD/anti-CD38-based regimens.

P2, N=61, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027

P2, N=208, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2029 --> Mar 2027 | Trial primary completion date: Feb 2029 --> Apr 2025

The effects of IMiDs (pomalidomide, lenalidomide) on CD38 expression and isatuximab-induced apoptosis, either alone or in combination with IMiDs, were also examined. Additionally, both antibodies effectively inhibited MM cell migration and significantly reduced cell adhesion. Their non-competitive binding and shared impact on cell dynamics suggest opportunities for optimizing treatment strategies through combinatorial or sequential approaches in MM therapy.

P1/2, N=30, Active, not recruiting, GlaxoSmithKline

P2, N=40, Recruiting, University of Utah | Not yet recruiting --> Recruiting

Novel CT-based quantification approaches for assessing BM involvement in the appendicular skeleton correlate with key clinical and PET parameters in MM. As low-dose, standardized techniques, they show promise for inclusion in MM imaging protocols, potentially enhancing assessment of disease extent and treatment response.

P1/2, N=23, Terminated, Sanofi | Phase classification: P1b/2 --> P1/2

P2, N=43, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed

CD38 mAb-containing induction regimens were associated with inferior stem cell mobilization yields and higher resource utilization. Extended washout periods modestly improved yield, highlighting a potential modifiable factor. These findings support the need for tailored mobilization strategies in CD38 mAb-exposed patients and warrant prospective evaluation of alternative mobilization agents and collection protocols to optimize efficiency and cost-effectiveness in the ASCT setting.

P2, N=50, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Mar 2025 --> Mar 2026

Not available.